The U.S. FDA named the first nine recipients of the recently unveiled commissioner’s national priority voucher (CNPV) program ...

Esperion Therapeutics Inc. has nominated ESP-2001 as a preclinical development candidate for the treatment of primary ...

Two enzymes from the protein disulphide isomerase (PDI) family enable prostate cancer cells to grow, survive, and resist ...

Total arterial revascularization (TAR) might not be the most popular approach to coronary artery bypass grafting (CABG), but it is gaining in popularity according to a new study appearing in the ...

Boston Scientific Corp. moved to acquire the balance of Nalu Medical Inc. in a $533 million cash deal, expanding its chronic pain portfolio with the addition of peripheral nerve stimulation. The Nalu ...

A year and half from its inception, Adcytherix SAS has raised a €105 million (US$122 million) series A, enabling it to take the lead antibody-drug conjugate (ADC) program into clinical development ...

NOD2 deficiency is involved in the pathogenesis of Crohn’s disease (CD) due to failure of gut innate immunity and loss of ...

Amphista Therapeutics Ltd. has nominated AMX-883, a selective and orally bioavailable degrader of BRD9, as its first clinical ...

Merit Medical Systems Inc. looks to ingest Pentax Medical’s C2 cryoballoon through a $22 million asset purchase expected to ...

ISS became the third proxy advisory firm to recommend shareholders vote against the proposed sale of Staar Surgical Co. to ...

Tumors suffer metabolic stress, such as oxygen and nutrient deficiency; as a result, altered metabolism is a common feature ...

Genedx LLC partnered with Illumina Inc. to test whether Illumina's constellation map read technology could shed light on hard ...